Skip Navigation

European Heart Journal 1982 3(6):583-586;
Copyright © 1982 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1982 by The European Society of Cardiology

European infarction study (EIS): A secondary prevention study with slow release oxprenolol after myocardial infarction

EUROPEAN INFARCTION STUDY GROUP

Received 18 April 1982; .

Abstract

The European Infarction Study (EIS) is a multicentre, double-blind placebo-controlled, randomised clinical trial planned to involve 4000 postinfarct patients. It was designed to test the efficacy of slow release oxprenolol 160 mg twice daily in the prevention of death and non-fatal cardiac events in the period 2–52 weeks following acute myocardial infarction. In a subsection of patients, 24 h ECG monitoring at specified intervals was undertaken in an attempt to determine the influence of treatment on the incidence of dysrhythmias and their relation to cardiac death in the patients studied.

Recruitment to the study was terminated on 6 July 1981, on the advice of the Review Committee. At the time the recruitment closed, 1741 patients had been admitted.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.